Clinical trials: End-Stage Heart Failure
Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy
Use of Beta-agonists in Stable Severe Congestive Heart Failure
The purpose of this study is to determine whether Salbutamol is effective in the treatment of severe heart failure due to ischemic and non- ischemic cardiomyopathy.
- Conditions
- Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure
- Trial name
- NCT01447069
- Testing
- Salbutamol
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Rabin Medical Center
HIV Infection, Advanced End Stage Heart Failure
HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients
This will be a prospective single-center interventional trial to compare the outcomes of HIV-positive heart transplant recipients by the HIV status of the donor; HIV-positive vs.
- Trial name
- NCT06659952
- Testing
- HIV-positive heart transplant
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Texas Southwestern Medical Center
End-stage Heart Failure
Long-Term Survival After LVAD Implantation in End-Stage Heart Failure
This is a prospective, observational, multi-center cohort study designed to evaluate long-term survival and clinical outcomes in patients with end-stage heart failure undergoing left ventricular assist device (LVAD) implantation.
- Trial name
- NCT07382284
- Testing
- Left Ventricular Assist Device (LVAD) implantation
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Liver Transplant; Complications, Ischemia Reperfusion Injury
Abdominal Regional Perfusion in Donation After Cardiac Death for Multi-Organ Transplantation
The main purpose of this study is to increase the pool of organs available for donation by performing ARP to recondition donation after cardiac death (DCD) organs prior to transplantation.
- Conditions
- Liver Transplant; Complications, Ischemia Reperfusion Injury, Cirrhosis, Liver Cancer
- Trial name
- NCT03946852
- Testing
- Abdominal Regional Perfusion
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre
Kidney Failure, Chronic, Heart Failure
Empagliflozin in ESKD - A Feasibility Study
The aim of this study is to learn about the safety of empagliflozin in dialysis patients as a preparation for a future large clinical trial.
- Trial name
- NCT05687058
- Testing
- Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing, Empagliflozin 10 mg daily dosing
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Mississippi Medical Center
Critical Illness, Chronic Disease
Improving Communication About Serious Illness
The purpose of this study is to improve care delivered to patients with serious illness by enhancing communication among patients, families, and clinicians in the outpatient setting.
- Conditions
- Critical Illness, Chronic Disease, Terminal Care, Palliative Care
- Trial name
- ICSI (NCT01933789)
- Testing
- Communication Feedback Form for Patients with Serious Illness
- Where
- 6 sites in United States
- Volunteers
- 817 people
- Sponsor
- University of Washington
Multiple Organ Failure, End Stage Cardiac Failure
Timing of Acute Palliative Care Consultation in Critically Ill Patients
A prospective randomized controlled trial studying the ordering of palliative care consultations in the emergency department (Ig) versus later palliative care consultations in the hospital--ICU or hospital ward(Cg).
- Conditions
- Multiple Organ Failure, End Stage Cardiac Failure, End Stage Chronic Obstructive Airways Disease, Chronic Kidney Disease Stage 5
- Trial name
- NCT02858778
- Testing
- Early order of palliative care consultation
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Wayne State University
End-stage Heart Failure, Cardiomyopathies
Evaluation of Platelet Therapy Response in Left Ventricular Assist Device Patients
The aim of this study is to evaluate the incidence of any hemocompatibility related adverse event (HRAE) after LVAD placement in patients responsive to a standard aspirin dose using point-of-care platelet inhibition monitoring…
- Conditions
- End-stage Heart Failure, Cardiomyopathies, Mechanical Circulatory Support
- Trial name
- NCT06152562
- Testing
- VerifyNow antiplatelet therapy response test
- Where
- Austria
- Volunteers
- 24 people
- Sponsor
- Medical University of Vienna
Kidney Disease, Peritoneal Dialysis (PD)
Sensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD)
To explore the use of the Bodyport Cardiac Scale in predicting worsening of events due to fluid overload in patients with kidney disease on peritoneal dialysis.
- Conditions
- Kidney Disease, Peritoneal Dialysis (PD), End Stage Kidney Disease (ESRD)
- Trial name
- SCALE-PD (NCT07059962)
- Testing
- Bodyport Cardiac Scale
- Where
- 7 sites in United States, Canada
- Volunteers
- 125 people
- Sponsor
- Bodyport Inc.
Renal Insufficiency, Chronic, Cardio-Renal Syndrome
Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD
In stage 3 chronic kidney disease (CKD) the risk of death due to cardiovascular causes is high and greatly exceeds the risk of progression to end stage renal failure.
- Trial name
- SPIRO-CKD (NCT02502981)
- Testing
- Spironolactone, Chlortalidone
- Where
- 4 sites in United Kingdom
- Volunteers
- 154 people
- Sponsor
- University Hospital Birmingham
End Stage Renal Disease
Monitoring in Dialysis -- a Prospective, Multi-center, Single-arm, Non-randomized, Observational Study in Patients Who Are Undergoing Hemodialysis.
The primary objective of this study is to estimate the proportion of hemodialysis patients experiencing clinically significant cardiac arrhythmias over a 6-month period using continuous cardiac monitoring with an implanted…
- Trial name
- MiD (NCT01779856)
- Testing
- REVEAL Insertable Cardiac Monitor (ICM)
- Where
- 10 sites in United States, India
- Volunteers
- 81 people
- Sponsor
- Medtronic Corporate Technologies and New Ventures
Pulmonary Arterial Hypertension
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
The purpose of this study is to find out if spironolactone added to ambrisentan for Pulmonary Arterial Hypertension (PAH) will increase exercise capacity.
- Trial name
- NCT02253394
- Testing
- Ambrisentan plus Spironolactone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Brigham and Women's Hospital
Dilated Cardiomyopathy (DCM), Heart Failure
Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy
To study the safety and efficacy of fibroblast activation protein (FAP)-targeted immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of end-stage dilated cardiomyopathy and provide a new method…
- Trial name
- NCT06902896
- Testing
- FAP immunosuppressive CAR-DC
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
End Stage Renal Disease (ESRD), Hemodialysis
Effect of Dialysis Techniques on Blood Pressure and Cardiac Function During Dialysis
Online hemodiafiltration confers a reduced mortality risk. However, it is not clear why HDF improved survival. To gain more insight in this issue, the effect of 4 dialysis techniques (differing in dialysate temperature and the…
- Conditions
- End Stage Renal Disease (ESRD), Hemodialysis, Hemodiafiltration, Intradialytic Hypotension
- Trial name
- HOLLANT (NCT03249532)
- Testing
- standard hemodialysis, cool hemodialysis, low volume hemodiafiltration
- Where
- 3 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- Amsterdam UMC, location VUmc
End Stage Renal Disease, Left Ventricular Hypertrophy
Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study
Kidney patients on dialysis commonly die because of heart disease. One of the biggest problems in their hearts is that the muscle wall of the heart thickens. This makes it less efficient.
- Trial name
- Altered (NCT01951404)
- Testing
- Allopurinol
- Where
- 3 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- University of Dundee
End Stage Renal Disease, Coronary Heart Disease
T Wave Alternans in Hemodialysis
The purpose of this study is to determine if the hemodialysis procedure changes the risk for cardiac arrest in patients.
- Conditions
- End Stage Renal Disease, Coronary Heart Disease, Congestive Heart Failure
- Trial name
- NCT00296543
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
Myocardial Stunning, End-stage Renal Disease
Myocardial Stunning During Hemodialysis: Role of Dialyste Calcium Concentration
Chronic kidney disease (CKD) is linked to elevated mortality rate, and cardiovascular disease is the main cause related to this outcome.
- Trial name
- NCT02545426
- Testing
- Change the dialysate calcium concentration
- Where
- Brazil
- Volunteers
- 19 people
- Sponsor
- University of Sao Paulo General Hospital
Coronary Artery Disease, End Stage Renal Disease
Coronary Revascularization in Patients On Dialysis in China-Retrospective Registry
Coronary artery disease (CAD) is the leading cause of death in end-stage renal disease (ESRD) patients requiring dialysis. There are limited data on clinical characteristics, treatment strategies and outcomes in this special…
- Conditions
- Coronary Artery Disease, End Stage Renal Disease, Dialysis
- Trial name
- CRUISE-R (NCT05841082)
- Where
- China
- Volunteers
- 1,249 people
- Sponsor
- China-Japan Friendship Hospital
Heart Failure, COPD
Ultrasound in Acute Dyspnea in the Field
Acute heart failure is one of the main causes of acute respiratory distres in prehospital emergency setting. The early and correct diagnosis is important because the misdiagnosis can result in deleterious consequeance to…
- Conditions
- Heart Failure, COPD, Asthma
- Trial name
- NCT01235182
- Where
- Slovenia
- Volunteers
- 248 people
- Sponsor
- University Medical Centre Maribor
Acute Coronary Syndrome, Chronic Kidney Disease
Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients
A 4 week-duration cross-over study on Ticagrelor and Clopidogrel for the Acute Coronary Syndrome (ACS) and Chronic Kidney Disease (CKD) subjects, focusing on the platelet inhibition and safety observation.
- Conditions
- Acute Coronary Syndrome, Chronic Kidney Disease, End-Stage Renal Disease
- Trial name
- APROVE-CKD (NCT02459288)
- Testing
- Clopidogrel first, Ticagrelor first
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Ping-Yen Liu